{"name":"Long Neck Medical Enterprises","slug":"long-neck-medical-enterprises","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AB PREP","genericName":"AB PREP","slug":"ab-prep","indication":"COVID-19 prevention","status":"phase_2"}]}],"pipeline":[{"name":"AB PREP","genericName":"AB PREP","slug":"ab-prep","phase":"phase_2","mechanism":"AB PREP is a therapeutic vaccine designed to stimulate an immune response against the SARS-CoV-2 virus.","indications":["COVID-19 prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBrbFY5MjJEV015dFlNOUhfUlVocG9WVmdZOThJTE5oLU0wX3lFUjdhckFMelItb05jV3JGeTBhUmlsYWE2LWZCWk5kbmF0T29BemEwZ3M3UjRxU0NWVmRsaDdvWnFOeWtKMHhoUTRWbWw1NnpT?oc=5","date":"2026-01-12","type":"deal","source":"Fierce Pharma","summary":"The top 10 biopharma M&A deals of 2025 - Fierce Pharma","headline":"The top 10 biopharma M&A deals of 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPbFdxZVgtN1JHTzZYSjNObVJXa0hYdlp1T3RuVU1yR3Npc1NwZ1FZbU12RkktMENQbG5rRjdIRnljYnJnYlpYamZuVUtCUWhwR0IxY1o5Z29qaV9FcTdGNGl5dDF1Tk4wX084UWlMdjVmRmNqeHc2eUVFNXl4SFFlVWloY3RiZVlRNVkyRm16RnR1UTBfeXJzYWVpSWJEdm9DSTZDV3ZrdG1Ia3hwQlEw?oc=5","date":"2026-01-12","type":"regulatory","source":"Fierce Pharma","summary":"JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority - Fierce Pharma","headline":"JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNeWJGX3A2ZThjSlJDTTRCSzRRaUVrTlk4YnJSTHNwT1JXOE5KQm93cnlhaG1iMl9FVlNBeUVjZTZlbWJldDBReG5vRTVmV0FMMk94TUtpZTZEaUJiQkxBQUpLSWItQWhvQ2lCZGwxSjJqZmg1bkFoT2dhelNxR1ZVSGxCWU9HS2s3UndFUk9ZTQ?oc=5","date":"2025-12-17","type":"pipeline","source":"BioSpace","summary":"6 Biotechs That Could Be Big Pharma’s Next M&A Target - BioSpace","headline":"6 Biotechs That Could Be Big Pharma’s Next M&A Target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNUzVNT2ZIcHd0V3QwSjAwR1d3cHVVWm51RDV4aU11QmNta2h6MW5xQmhydndQYWlTYkNkeGtOa2o0WXFRQnpDaVVWRjRvYlFOT1BBc0xjRHRFNDRjTk9FRjRqLXJMR0EyRjU1SnV0UmN2eU1PQUlmSWFZNk9Fb0pTV3NFdnJyMHJQWDF3bkNXUXJMaTEwa0tfUmpUb3dwa25fSW55djAzY2Z3ZTVf?oc=5","date":"2025-11-24","type":"pipeline","source":"Business Insider","summary":"The 18 most promising startups in healthcare in 2025, according to investors - Business Insider","headline":"The 18 most promising startups in healthcare in 2025, according to investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPSVA1c3d6ZDl0LUwydF9OV3Z6VVlmZEZBNkF3ZWlLU1FsQTRhanlKd3lvWExrM3VDa0FleXZpT0d4cTZ2UEQ4RktMUnA0UlFlTzd5X0JuYnJrWDVsbjhPaWZwdEYzeVdyVUUwMFNRS3gySmpOMUlCaXpSNlJCM0p4clZWcjFxT3h5NjRoSWhlQjQwdmhQX2xGczdYS2pvWXVjRzlhMWNxdXA0Y3ZWT2pqZVYtRC1uWUZJNkxDdnlLWGRoSTJIRUZfcU9WU2p4MXMxbl9rUDA5bTJCZlNmRjJtWV8yZC0?oc=5","date":"2025-10-27","type":"pipeline","source":"Medical Republic","summary":"Should drug companies be allowed to run ‘awareness’ ads for conditions their drugs treat? We asked five experts - Medical Republic","headline":"Should drug companies be allowed to run ‘awareness’ ads for conditions their drugs treat? We asked five experts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5POGVrbHlSbnRtOWJ1UkFTSXhKMndhNVpnaDJEVktKWS1sQU9zWEJ2Z09RZzFJaENBWlF6THE1RV9FT2hrbUM3OUNrWXE4OEtSN2FKbGJSWjlnUE13ZEdyRzJRUmpjV0xTQXU4R0FXLV9xV0w1Vm16Wg?oc=5","date":"2025-07-31","type":"regulatory","source":"CNN","summary":"Trump is demanding drugmakers lower prices within 60 days. Pharma experts say it’s unlikely to happen. - CNN","headline":"Trump is demanding drugmakers lower prices within 60 days. Pharma experts say it’s unlikely to happen.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOUk5WVk5zV2hKdGZBLU5aS2NQU0RHTEQ1c0ptaFo2UUpBTGt4WnRmZWFMZmN0SWdWY1RuLXl0YUd5c3QtUFdDZVNTSzBBQ2NhUWx4N19ob3g2THJOU2JnWXQtVmdtWEN6SXpaN2Z0NEttaTlDX1pxblZ6VU5ZNS15T0NwamppbHg5MG50OXFHQU5QQ25PSkpwbDlHYUZwMXRWWWpVYWt30gGrAUFVX3lxTE8ySHE4UU1FdkZoQVk1NkNONVFOQU5CT0xSbGhsMnEzNjY4blBSakFDS3c4dXhkVW9QSlJBWkJDWUJUS0JFXzNLLWNYRlB1X2xzUU9pWTRTTE5WalB3RlZPNnJzc1oyZUpCMmxsVVRrWTRENUppTFlaNmZBc1VRdlN4bFkzQ3FmZXhsTnZkcXMybDd0LXFDeHlYZGpzZ2wxVF9la1ZheWVWcm5lOA?oc=5","date":"2025-06-17","type":"pipeline","source":"CNBC","summary":"Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC","headline":"Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOTWhjNzk1Y2Y0elFvVmd3eWUwWU5xRExCS29FS0lsMmRaZ3JPMWJfd0JQdUNlX1JkbDRjTzR6OEtXcmI3X1FoVlQtWjQ3SVpLQS0tYU50SHBIaU43ZnV2UjY2TG1YaHJjc3BXeWxELVRiR3RnNlh1RGlfT3M4VE1uakhCRENMMHQ0UG93MXp6eFIyMkdPaGVsd3pWcW9CTUZ5SUxRZFpCY9IBrwFBVV95cUxQZFpRSjFod1pSeVJ6dHhfc200X2ZYWnVLS1ZDTHF0ZndNcmx0N3M5dGZZclc4cXZUWUQ4MmVhdUtOSUNFdElQVFFTY3BTOFY3WEdJZlFWWlFSM1MyM0xGaWZNaVRES2s4ZjQ4aW9DaVR4NFR2djVpWnBMQXVBVGRzNUNCRlpfSEQ1WmwxN1hGRkxIVU10ZENyLXRtOE91TUtiOVpWT3U0cW5aNFZwNVZz?oc=5","date":"2025-02-03","type":"pipeline","source":"Delaware Business Times","summary":"TidalHealth expands footprint with new campus build in Millsboro - Delaware Business Times","headline":"TidalHealth expands footprint with new campus build in Millsboro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQd1dBVzlnQUsxWEJMSjNnSDFHZHBwSldGR3g0V2R6a1dOTldka09mOUFRM0ZvTlV4enlvQmItbGljWWxQODk1ejVJbEd6Vjc3QzNTWUlUUUE3UzhManpCZVEwZzNUMGVUZGgxVXkyLWh4OTFLVC1jWlpnMjBQQWRhWHR0TkRHWHl0MFRjY1RJQQ?oc=5","date":"2024-10-22","type":"pipeline","source":"Labiotech.eu","summary":"Eight nanotechnology companies to watch out for - Labiotech.eu","headline":"Eight nanotechnology companies to watch out for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxONHZOcllYSGhhYml5VUZMdEUxV2FIUmJxTUpYZXl6SVVWZjFBM20tVk5nWC0ydHowWDJGeENLSW0tZkpiWlliN29tR1F3RjhLNjEtU1F2UkJTZXJ3bGNqMElqcFFNckIzU3dEVlpybUxRaG4ySjk4MjhNVFo3SnByU2ZJWVptb3RaVFlyODV4VEVSQ3BOZ2ZIZTFWNDdxZzVtREtGRzZoc1FwcW56djJNYg?oc=5","date":"2024-05-08","type":"pipeline","source":"Investing News Network","summary":"Canadian Pharma Stocks: 5 Biggest Companies - Investing News Network","headline":"Canadian Pharma Stocks: 5 Biggest Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFByS0xPN2QwRkpHVDAzZUJYVjhDSGE4eERabGp2Y091VHlKcnYwZ3BSTlFiX3JtVjdjdFVweHp3bk1OUTRzWjc2MDVIM2ZTSkwzYjdEYVJTMWFFamJGWnRWaERPU0duczhxWENmeTBDUFpHLXhNM21SWmh4a3k1UQ?oc=5","date":"2020-09-22","type":"pipeline","source":"Fortune","summary":"Commentary: My cancer might be back—and I wonder if unnecessary radiation caused it in the first place - Fortune","headline":"Commentary: My cancer might be back—and I wonder if unnecessary radiation caused it in the first place","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBPVVB2M3ZNbzFfRU1BUGxoMzB1bjNVZlM2d2g3LUpxel9YaXh2UXZFVW5hYjdnLTBQSkh6SWpuNFZUeFJ6RjZFMnlJUkx5aF9oOTBFS2N0VlZQMGllUUVBMw?oc=5","date":"2017-01-05","type":"pipeline","source":"NEJM","summary":"The Large Pharmaceutical Company Perspective - NEJM","headline":"The Large Pharmaceutical Company Perspective","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}